- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
More stores do not equal faster growth.
Has the pharmaceutical company really changed its strategy?
When the bearish bet isn't about instant gratification.
Two companies come off the list because of improved outlook and a sale.
Something is amiss these days.
For only $1, we’ll give you everything we got -- 12 different products -- until the ball drops on New Year’s Eve.
Its stock price notwithstanding.
This is moved to a red flag from a yellow.
But suing Audit Integrity wasn't such a good idea.
While the medial device company's latest earnings beat expectations, its sales were a disappointment.